Studybox Research 510(k) Clinical Studies

Point-of-Care Cardiac Troponin Test

Clinical and analytical performance to support substantial equivalence.

Studybox

510(k) Clinical Studies

A point-of-care troponin study is a pivotal clinical investigation in all but name. Patients presenting to emergency departments with suspected acute coronary syndrome are enrolled, serial samples are drawn at protocol-defined times alongside standard care, and a blinded committee adjudicates whether each patient had a myocardial infarction using the Universal Definition. Device results are evaluated against both the laboratory troponin assay and the adjudicated diagnosis, and sample size is set by the number of adjudicated infarctions, not by the number of patients.

High-sensitivity troponin raises the analytical bar as well. Sex-specific 99th percentile upper reference limits must be established in a well-characterized healthy population, and imprecision at those limits must meet the accepted definition of a high-sensitivity assay. Point-of-care platforms using whole blood face the added question of agreement between whole blood and plasma at the very low concentrations where rule-out decisions are made.

Analyte: Cardiac troponin I or T (cTnI or cTnT), including high-sensitivity assays
Therapeutic area: Cardiovascular Disease
Specimens: Venous Whole Blood, Serum and Plasma, Capillary Fingerstick Blood
Intended-use settings: emergency department, hospital POC
Operators: Emergency department and hospital point-of-care staff, typically nurses and clinical technicians working under the hospital laboratory's CLIA certificate.
Comparator: Typically a central laboratory cardiac troponin assay (often high-sensitivity) for method comparison, and an adjudicated final clinical diagnosis of myocardial infarction based on the Universal Definition of Myocardial Infarction for clinical performance.

510(k) Studies specifics

What Changes for This Assay on This Pathway.

The clinical study enrolls consecutive emergency department patients with suspected ACS, with final diagnosis adjudicated by cardiologists blinded to the investigational result and using the laboratory troponin; the endpoint committee charter is typically part of the protocol.
The reference population study for the 99th percentile URL requires screening healthy subjects (often with natriuretic peptide, HbA1c and eGFR to exclude subclinical disease) and reporting sex-specific limits with confidence intervals and imprecision at those limits.
Rapid rule-out algorithms (single-sample or 0/1-hour) proposed in labeling require their own analysis and are typically discussed in a pre-submission because they introduce clinical decision claims.
Whole blood versus plasma agreement at low concentrations and the effect of hematocrit on whole blood results are recurring analytical questions for point-of-care platforms.

Endpoints the study must support

Clinical sensitivity, specificity, negative predictive value and positive predictive value for acute myocardial infarction at the proposed cutoff(s), at presentation and at protocol-defined serial time points
Method comparison against the laboratory troponin assay across the measuring range
Sex-specific 99th percentile upper reference limits determined in a healthy reference population, with imprecision at those limits
Performance of any rapid rule-out or rule-in algorithm proposed in labeling

Enrollment realities

Driven by adjudicated myocardial infarctions, which are a minority of chest pain presentations; studies enroll many patients across multiple emergency departments and run for a year or more. Consent windows are short and research staff must be present around the clock to capture presentation samples.

How Studybox runs it

Pre-Qualified Sites, Embedded Coordinators.

Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →

Relevant FDA guidance

FAQ

Point-of-Care Cardiac Troponin Test Study Questions.

01 Who operates the point-of-care cardiac troponin test in a 510(k) studies study?

Emergency department and hospital point-of-care staff, typically nurses and clinical technicians working under the hospital laboratory's CLIA certificate.

02 What is the comparator for a point-of-care cardiac troponin test study?

Typically a central laboratory cardiac troponin assay (often high-sensitivity) for method comparison, and an adjudicated final clinical diagnosis of myocardial infarction based on the Universal Definition of Myocardial Infarction for clinical performance.

03 What drives enrollment for a point-of-care cardiac troponin test study?

Let's talk IVD research

Planning a point-of-care cardiac troponin test study?

Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.